Skip to main content

2023 SSO Annual Meeting Main banner

Tweets by 2023 SSO Annual Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Speaker

Browse by Speaker

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

U
Ugras, Stacy

Columbia University Medical Center
P2: Incidence of lymph node involvement in clinically node-negative breast cancer patients following neoadjuvant chemotherapy and identification of clinicopathologic features which may lead to omission of sentinel lymph node biopsy
Location:SSO HUB: Breast & Endocrine Zone
Stacy Ugras
Ullman, Nicholas

University of Rochester Medical Center
38: Semaphorin 4D is Expressed by Activated Lymphocytes in Pancreatic Adenocarcinoma, and Monoclonal Blockade Sensitizes Murine Tumors to Immune Checkpoint Therapy
Location:Ballroom B
Nicholas Ullman
46: Pan-Lysyl Oxidase Inhibition Disrupts Macrophage Invasion and Renders Tumor-Associated Macrophages Susceptible to Cytotoxic Chemotherapy in Cholangiocarcinoma
Location:Ballroom A
Nicholas Ullman
P34: Determining Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma, A Phase I Study
Location:SSO HUB Pan-Tumor Zone: CRS, HPB, Pan-Tumor & Upper GI
Nicholas Ullman
P45: Dietary fish oil impairs melanoma growth and augments the tumor immune microenvironment in anti-PD-1 treated melanoma
Location:SSO HUB: Melanoma & Sarcoma Zone
Nicholas Ullman
Uronis, Hope

Duke University Medical Center
52: Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.
Location:Ballroom A
Hope Uronis